Xeris Biopharma Q1 2023 Earnings Report $3.75 -0.22 (-5.54%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Xeris Biopharma EPS ResultsActual EPS-$0.12Consensus EPS -$0.17Beat/MissBeat by +$0.05One Year Ago EPSN/AXeris Biopharma Revenue ResultsActual Revenue$33.20 millionExpected Revenue$30.77 millionBeat/MissBeat by +$2.43 millionYoY Revenue GrowthN/AXeris Biopharma Announcement DetailsQuarterQ1 2023Date5/9/2023TimeN/AConference Call ResourcesPress ReleaseXERS Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Xeris Biopharma Earnings HeadlinesXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 50% stake, while 45% is held by institutionsFebruary 20 at 4:37 AM | finance.yahoo.comThe American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and AwarenessJanuary 21, 2025 | prnewswire.comWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.February 22, 2025 | Behind the Markets (Ad)Xeris Expects to Exceed Full-Year 2024 Financial GuidanceJanuary 10, 2025 | finance.yahoo.comXeris to Participate in Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | businesswire.comAnalysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before LongNovember 18, 2024 | finance.yahoo.comSee More Xeris Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xeris Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xeris Biopharma and other key companies, straight to your email. Email Address About Xeris BiopharmaXeris Biopharma (NASDAQ:XERS), a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.View Xeris Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
